Guido Pickert
Head of Investor Relations
Thank you, operator. First of all, I would like to impress a thank you, a very big thank you for your continued support of Gerresheimer. We have not had an earnings call for quite some time as we fully focused on completing our investigations and ensuring clean, robust and especially compliant set of 2025 financials. This was accomplished today, and we were able to publish our audited 2025 annual report. Our Management Board will explain our results in more detail.
First, on the disclaimer. Please let me remind you that the disclaimer you can find in our full year 2025 slide deck will apply throughout this earnings call, and we assume your content to this — consent to this. I will, therefore, not read it out loud. Please allow me some selected clarification. Due to rounding, numbers presented throughout this report may not add up precisely to the totals indicated and percentages may not precisely reflect the absolute figures for the same.
Organic revenue and organic adjusted EBITDA include the revenues and adjusted EBITDA of Bormioli Pharma in both 2024 and 2025, which we acquired in December 10, 2024, and fully consolidate from the beginning of the financial year 2025, translated at the budgeted exchange rates for the financial year 2025.
Thank you. And now let me introduce today’s speakers on
